These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 14599082)

  • 1. Cancer therapies crisis in the USA.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2003 Oct; 3(5):579-82. PubMed ID: 14599082
    [No Abstract]   [Full Text] [Related]  

  • 2. Cancer drug approval in the United States, Europe, and Japan.
    Milsted RA
    Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686
    [No Abstract]   [Full Text] [Related]  

  • 3. Antiangiogenic therapy for cancer: an update.
    Shojaei F; Ferrara N
    Cancer J; 2007; 13(6):345-8. PubMed ID: 18032969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Researchers left to guess at outcomes of most cancer clinical trials.
    Twombly R
    J Natl Cancer Inst; 2009 Jan; 101(2):72-4. PubMed ID: 19141774
    [No Abstract]   [Full Text] [Related]  

  • 5. Cancer therapy reform.
    Levinson AD
    Science; 2010 Apr; 328(5975):137. PubMed ID: 20378778
    [No Abstract]   [Full Text] [Related]  

  • 6. FDA likely to further restrict erythropoietin use for cancer patients.
    Fox JL
    Nat Biotechnol; 2007 Jun; 25(6):607-8. PubMed ID: 17557084
    [No Abstract]   [Full Text] [Related]  

  • 7. Approval may embolden industry to combine cancer therapies.
    Deng B
    Nat Med; 2015 Feb; 21(2):105. PubMed ID: 25654594
    [No Abstract]   [Full Text] [Related]  

  • 8. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trouble at the office.
    Allison M
    Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797
    [No Abstract]   [Full Text] [Related]  

  • 10. Cancer drugs. Weighing the risks and benefits.
    Bren L
    FDA Consum; 2007; 41(1):10-9. PubMed ID: 17342832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Swimming upstream: an advocate reflects on cancer research and social realities.
    Mayer M
    J Clin Oncol; 2008 Jun; 26(16):2783-6. PubMed ID: 18509190
    [No Abstract]   [Full Text] [Related]  

  • 12. The ODAC Chronicles: Part 4. Hurdles pre and post accelerated approval.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Apr; 5(2):197-200. PubMed ID: 15877516
    [No Abstract]   [Full Text] [Related]  

  • 13. Targeted agents: the rules of combination.
    Kwak EL; Clark JW; Chabner B
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5232-7. PubMed ID: 17875749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can single-patient investigational new drug studies hurry slow trains to the fast track?
    Chenoweth D
    Drug Discov Today; 2006 Mar; 11(5-6):185-6. PubMed ID: 16580594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Better prioritization may speed approval of adjuvant therapies in breast cancer.
    Tuma RS
    J Natl Cancer Inst; 2008 Jun; 100(12):842-4. PubMed ID: 18544735
    [No Abstract]   [Full Text] [Related]  

  • 16. HDAC inhibitors overcome first hurdle.
    Garber K
    Nat Biotechnol; 2007 Jan; 25(1):17-9. PubMed ID: 17211382
    [No Abstract]   [Full Text] [Related]  

  • 17. Food and Drug Administration approval process for ophthalmic drugs in the US.
    Lloyd R; Harris J; Wadhwa S; Chambers W
    Curr Opin Ophthalmol; 2008 May; 19(3):190-4. PubMed ID: 18408492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ODAC chronicles--part 2. Statistics and clinical medicine in the USA: the triumph of science over art?
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):941-4. PubMed ID: 15606323
    [No Abstract]   [Full Text] [Related]  

  • 19. The ODAC Chronicles: Part 6a. ODAC's structure and function.
    Grillo-López AJ
    Expert Rev Anticancer Ther; 2005 Aug; 5(4):573-7. PubMed ID: 16111457
    [No Abstract]   [Full Text] [Related]  

  • 20. A merger too far?
    Wadman M
    Nature; 2007 Mar; 446(7131):15. PubMed ID: 17330017
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.